NCRI Press Release, 8 November 2010
Date published: Nov 08 2010
Test selects 60 per cent of women with inherited ovarian cancer who could benefit from ‘smart’ drug
Download the attachment
Recent Tweets
-
⏰ Last chance to register! ⏰ Secure your place at the #NCRIVirtual Showcase to discover the latest #cancerresearch… https://t.co/g6N27nXUGy
19 hours ago -
Join us on 12 Nov to discover the role of patient and public involvement in #cancerresearch & how you can make a di… https://t.co/yK5fAeJ5kQ
21 hours ago -
📰PRESS RELEASE: Study of #COVID-19 levels in #oncology staff suggests need for more extensive testing. Read the ful… https://t.co/l0vJpNWR5x
22 hours ago
- 19 Mar 2020Workstream leads: NCRI Skin Group
- 26 Nov 2019CM-Path - Application for Consumer Membership (Deadline - 1st January 2020)
- 20 Nov 2019With its new chair, Professor David Harrison, at the helm, CM-Path share top priorities
- 19 Jul 2019Consumer (Patient / Carers) vacancies for NCRI Groups available. Apply today!
- 20 May 2019Celebrating ten years of NCRI’s Clinical and Translational Radiotherapy Research Group
- 29 Apr 2019NCRI and The British Society for Immunology announce new partnership
- 14 Mar 2019Register now for the NCRI CTU Annual Trials Meeting: 17 June 2019
RSS Feed